259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

Inicio・Lista de Acciones・Nanobiotix

N
Nanobiotix

Cerrado

7.85 5.23

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.37

Máximo

8.03

Métricas clave
By Trading Economics
Ingresos	-46M
Ventas	-21M
Margen de beneficios	221.361
Empleados	108
EBITDA	-38M

Dividendos
By Dow Jones
Próximas Ganancias	17 sept 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	370M
Apertura anterior	2.62
Cierre anterior	7.85

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

2.975 / 3.015 Soporte y Resistencia

Nanobiotix Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2025, 23:37 UTC

Acciones populares

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept 2025, 20:41 UTC

Ganancias

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept 2025, 20:30 UTC

Ganancias

GameStop 2Q Sales, Profit Rise

9 sept 2025, 23:19 UTC

Charlas de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept 2025, 21:35 UTC

Ganancias

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 21:32 UTC

Ganancias

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 sept 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept 2025, 20:26 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:23 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:12 UTC

Ganancias

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept 2025, 20:07 UTC

Ganancias

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Rev $14.93B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q EPS $1.01 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Synopsys 3Q EPS $1.50 >SNPS

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Hardware Revenue $670M >ORCL

Comparación entre iguales

Cambio de precio

Nanobiotix previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Nanobiotix Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

2.975 / 3.015Soporte y Resistencia

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.